
Pfizer invested in Bamboo in the first quarter and has agreed to pay up to $645m in total to acquire the company, depending on milestones.
A round up of all the latest news on www.globalcorporateventuring.com for our subscribers.
General Electric has made its third investment in the blood flow monitoring technology developer, which has reportedly raised $75m since 2012.
Ambrx, which agreed an acquisition last year by a Fosun Pharma and WuXi PharmaTech-backed consortium, has secured funding from investors including Fosun, Sinopharm and Humanwell.
Roche's corporate venturing unit co-led the latest round to be closed by the healthcare analytics provider, which will be used for product development.
Healthkart, owned by Intel-backed Bright Lifecare, has added $12m to its coffers thanks to Sequoia Capital and Kae Capital.
Bioniz has secured $13m in a round co-led by Takeda Ventures and David Pyott, who has been named chairman of the immuno-inflammatory disease drug developer.
Big Health, developer of a product that helps people combat insomnia, has been backed by Kaiser Permanente in its third funding round.